Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Tainan, Taiwan.
Department of Respiratory Therapy, Fu Jen Catholic University, New Taipei City, Taiwan; Department of Internal Medicine, New Taipei City Hospital, New Taipei City, Taiwan.
J Microbiol Immunol Infect. 2014 Dec;47(6):491-6. doi: 10.1016/j.jmii.2013.06.007. Epub 2013 Aug 24.
BACKGROUND/PURPOSE: To investigate the clinical characteristics of Clostridium difficile infection (CDI) at a medical center in Taiwan.
Patients with CDI were identified from medical records at the National Taiwan University Hospital (Taipei, Taiwan). The following information was gathered and analyzed to better understand the clinical manifestations of CDI: age; sex; underlying immunocompromised conditions; laboratory data; in-hospital mortality; and previous use of drugs such as antimicrobial agents, steroids, and antipeptic ulcer agents.
During the years 2000-2010, 122 patients were identified as having CDI. This included 92 patients with nontoxigenic CDI (i.e., positive stool culture for C. difficile but negative results for toxins A and B) and 30 patients with toxigenic CDI (i.e., positive stool culture cultures for C. difficile and positive results for toxins A and B). Of the 122 patients, 48 (39%) patients were older than 65 years and most patients acquired the CDI while in the hospital. Active cancer was the most common reason for hospitalization, followed by diabetes mellitus, and end-stage renal disease. More than 90% of the patients had received antibiotics before acquiring CDI. The results of fecal leukocyte examinations were positive in 33 (27%) patients. The overall in-hospital mortality rate was 26.2%. There were no significant differences between patients with nontoxigenic CDI and patients with toxigenic CDI.
Clostridium difficile infection can develop in healthcare facilities and in community settings, especially in immunocompromised patients.
背景/目的:调查台湾一家医学中心艰难梭菌感染(CDI)的临床特征。
从国立台湾大学医院(台北,台湾)的病历中确定 CDI 患者。收集和分析以下信息,以更好地了解 CDI 的临床表现:年龄;性别;潜在的免疫功能低下状况;实验室数据;住院死亡率;以及先前使用抗菌药物、类固醇和抗溃疡药物等药物的情况。
在 2000-2010 年期间,确定了 122 例 CDI 患者。其中 92 例为非产毒 CDI(即粪便培养艰难梭菌阳性但毒素 A 和 B 检测阴性),30 例为产毒 CDI(即粪便培养艰难梭菌阳性且毒素 A 和 B 检测阳性)。在 122 例患者中,48 例(39%)患者年龄大于 65 岁,大多数患者在住院期间感染 CDI。活动性癌症是住院的最常见原因,其次是糖尿病和终末期肾病。超过 90%的患者在感染 CDI 前接受过抗生素治疗。33 例(27%)患者粪便白细胞检查结果阳性。总的住院死亡率为 26.2%。非产毒 CDI 患者和产毒 CDI 患者之间无显著差异。
艰难梭菌感染可在医疗机构和社区环境中发生,尤其是在免疫功能低下的患者中。